Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses · References

References

CC BY 4.0 · NIHR Journals Library · approximately 15 min read

  1. Bedford J, Harford M, Petrinic T, Young JD, Watkinson PJ. Risk factors for new-onset atrial fibrillation on the general adult ICU: protocol for a systematic review. BMJ Open 2018;8:e024640. 10.1136/bmjopen-2018-024640
  2. Artucio H, Pereira M. Cardiac arrhythmias in critically ill patients: epidemiologic study. Crit Care Med 1990;18:1383–8. 10.1097/00003246-199012000-000152245612
  3. Walkey AJ, Greiner MA, Heckbert SR, Jensen PN, Piccini JP, Sinner MF, et al. Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am Heart J 2013;165:949–55.e3. 10.1016/j.ahj.2013.03.02023708166
  4. Knotzer H, Mayr A, Ulmer H, Lederer W, Schobersberger W, Mutz N, Hasibeder W. Tachyarrhythmias in a surgical intensive care unit: a case-controlled epidemiologic study. Intensive Care Med 2000;26:908–14. 10.1007/s00134005128010990105
  5. Kuipers S, Klein Klouwenberg PM, Cremer OL. Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review. Crit Care 2014;18:688. 10.1186/s13054-014-0688-525498795
  6. Samet P, Bernstein W, Levine S. Significance of the atrial contribution to ventricular filling. Am J Cardiol 1965;15:195–202. 10.1016/0002-9149(65)90454-614254811
  7. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998;32:197–204. 10.1016/S0735-1097(98)00221-69669270
  8. Kanji S, Williamson DR, Yaghchi BM, Albert M, McIntyre L, Canadian Critical Care Trials Group. Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients. J Crit Care 2012;27:326.e1–8. 10.1016/j.jcrc.2011.10.011
  9. Clayton B, Ball S, Read J, Waddy S. Risk of thromboembolism in patients developing critical illness-associated atrial fibrillation. Clin Med 2018;18:282–7. 10.7861/clinmedicine.18-4-282
  10. Wetterslev M, Haase N, Hassager C, Belley-Cote EP, McIntyre WF, An Y, et al. New-onset atrial fibrillation in adult critically ill patients: a scoping review. Intensive Care Med 2019;45:928–38. 10.1007/s00134-019-05633-x31089761
  11. Bedford JP, Gerry S, Hatch RA, Rechner I, Young JD, Watkinson PJ. Hospital outcomes associated with new-onset atrial fibrillation during ICU admission: a multicentre competing risks analysis. J Crit Care 2020;60:72–8. 10.1016/j.jcrc.2020.07.00932763777
  12. Fernando SM, Mathew R, Hibbert B, Rochwerg B, Munshi L, Walkey AJ, et al. New-onset atrial fibrillation and associated outcomes and resource use among critically ill adults – a multicenter retrospective cohort study. Crit Care 2020;24:15. 10.1186/s13054-020-2730-031931845
  13. Arrigo M, Feliot E, Gayat E, Mebazaa A. Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: a report from the FROG-ICU study. Int J Cardiol 2018;270:203. 10.1016/j.ijcard.2018.07.08030045823
  14. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest 2014;146:1187–95. 10.1378/chest.14-000324723004
  15. National Institute for Health and Care Excellence (NICE). Atrial Fibrillation: Management. Clinical Guideline [ CG180 ]. London: NICE; 2014. URL: www.nice.org.uk/guidance/cg180 (accessed 1 October 2020).
  16. Chean CS, McAuley D, Gordon A, Welters ID. Current practice in the management of new-onset atrial fibrillation in critically ill patients: a UK-wide survey. PeerJ 2017;5:e3716. 10.7717/peerj.371628929012
  17. Drikite L, Bedford JP, O’Bryan L, Petrinic T, Rajappan K, Doidge J, et al. Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review. Crit Care 2021;25:257. 10.1186/s13054-021-03684-534289899
  18. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8:19–32. 10.1080/1364557032000119616
  19. Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci 2010;5:69. 10.1186/1748-5908-5-6920854677
  20. Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team’s experience with Arksey and O’Malley’s framework. BMC Med Res Methodol 2013;13:48. 10.1186/1471-2288-13-4823522333
  21. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018;169:467–73. 10.7326/M18-085030178033
  22. Watkinson P, Johnson A, Rajappan K, Corbett M, Mouncey P, Harrison DA, et al. Critical care Atrial Fibrillation Evaluation (CAFE): Protocol. 2019. URL: https://fundingawards.nihr.ac.uk/award/17/71/04 (accessed 1 October 2019).
  23. Bedford JP, Harford M, Petrinic T, Young JD, Watkinson PJ. Risk factors for new-onset atrial fibrillation on the general adult ICU: a systematic review. J Crit Care 2019;53:169–75. 10.1016/j.jcrc.2019.06.01531247516
  24. Yokota T, Uchino S, Yoshida T, Fujii T, Takinami M. Predictors for sustained new-onset atrial fibrillation in critically ill patients: a retrospective observational study. J Anesth 2018;32:681–7. 10.1007/s00540-018-2537-130066166
  25. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. 10.1136/bmj.l489831462531
  26. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. 10.1136/bmj.i491927733354
  27. Launey Y, Lasocki S, Asehnoune K, Gaudriot B, Chassier C, Cinotti R, et al. Impact of low-dose hydrocortisone on the incidence of atrial fibrillation in patients with septic shock: a propensity score-inverse probability of treatment weighting cohort study. J Intensive Care Med 2019;34:238–44. 10.1177/088506661769684728292220
  28. Walkey AJ, Evans SR, Winter MR, Benjamin EJ. Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: a propensity-matched cohort study. Chest 2016;149:74–83. 10.1378/chest.15-095926270396
  29. Walkey AJ, Quinn EK, Winter MR, McManus DD, Benjamin EJ. Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis. JAMA Cardiol 2016;1:682–90. 10.1001/jamacardio.2016.218127487456
  30. Balser JR, Martinez EA, Winters BD, Perdue PW, Clarke AW, Huang W, et al. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology 1998;89:1052–9. 10.1097/00000542-199811000-000049821992
  31. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:1149–53. 10.1097/00003246-200106000-0001111395591
  32. Gerlach A, Kane-Gill S, F Dasta J, Steinberg S, C Martin L, Cook C. Diltiazem versus amiodarone for new-onset atrial arrhythmias in non-cardiac post surgical patients: a cohort study. Crit Care Shock 2008;11(3).
  33. Cho MS, Nam G-B, Kim YN, Hwang J, Kim M, Lee JH, et al. Abstract 20382: comparison of outcomes after rhythm or rate control strategy for the new-onset atrial fibrillation in critically ill sepsis patients managed in the medical intensive care unit. Circulation 2017;136:A20382-A.
  34. Matsumoto Y, Shibata SC, Maeda A, Imada T, Okitsu K, Fujino Y. Comparison of the Short Acting Beta1 Blocker Landiolol with Amiodarone for Pharmacological Cardioversion for Atrial Fibrillation in Intensive Care Unit Patients. Proceedings of the 2015 Annual Meeting of the International Anesthesia Research Society, 21–24 March 2015, Honolulu, HI, USA. 10.1213/01.ane.0000470325.07465.0f
  35. Balik M, Kolnikova I, Maly M, Waldauf P, Tavazzi G, Kristof J. Propafenone for supraventricular arrhythmias in septic shock-comparison to amiodarone and metoprolol. J Crit Care 2017;41:16–23. 10.1016/j.jcrc.2017.04.02728463737
  36. Mieure KD, Moranville MP, Park JJ, Lat I, Jennings HR, Lazar S, et al. A Comparison of Intravenous Rate Control Agents for New Onset Atrial Fibrillation with Rapid Ventricular Rate. Proceedings of the 32nd Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm, 4–7 May 2011, San Francisco, CA, USA.
  37. Jaffer F, Anand S, Ajay-obe A, Parbtani R, Doraiswamy V, Malo J. Use of amiodarone in management of atrial tachyarrhythmia in septic shock. Chest 2016;150:361A. 10.1016/j.chest.2016.08.374
  38. Brown M, Nassoiy S, Chaney W, Plackett TP, Blackwell RH, Luchette F, et al. Impact and treatment success of new-onset atrial fibrillation with rapid ventricular rate development in the surgical intensive care unit. J Surg Res 2018;229:66–75. 10.1016/j.jss.2018.03.00929937018
  39. Sleeswijk ME, Tulleken JE, Van Noord T, Meertens JH, Ligtenberg JJ, Zijlstra JG. Efficacy of magnesium-amiodarone step-up scheme in critically ill patients with new-onset atrial fibrillation: a prospective observational study. J Intensive Care Med 2008;23:61–6. 10.1177/088506660731018118320707
  40. Slavik RS, de Lemos J, Gorman SK, Buchkowsky S. Patterns of practice for the acute management of new-onset atrial fibrillation in critically-ill intensive care unit patients. Crit Care Med 2003;31:A137-A.
  41. Liu WC, Lin WY, Lin CS, Huang HB, Lin TC, Cheng SM, et al. Prognostic impact of restored sinus rhythm in patients with sepsis and new-onset atrial fibrillation. Crit Care 2016;20:373. 10.1186/s13054-016-1548-227855722
  42. Mitrić G, Udy A, Bandeshe H, Clement P, Boots R. Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. Crit Care 2016;20:90. 10.1186/s13054-016-1252-227038791
  43. Mayr AJ, Dünser MW, Ritsch N, Pajk W, Friesenecker B, Knotzer H, et al. High-dosage continuous amiodarone therapy to treat new-onset supraventricular tachyarrhythmias in surgical intensive care patients: an observational study. Wien Klin Wochenschr 2004;116:310–17. 10.1007/BF0304090115237656
  44. Burris JM, Subramanian A, Sansgiry S, Palacio CH, Bakaeen FG, Awad SS. Perioperative atrial arrhythmias in noncardiothoracic patients: a review of risk factors and treatment strategies in the veteran population. Am J Surg 2010;200:601–5. 10.1016/j.amjsurg.2010.07.01921056136
  45. Nakamura K, Inokuchi R, Hiruma T, Tokunaga K, Doi K, Nakajima S. Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. J Anesth 2016;30:891–4. 10.1007/s00540-016-2199-927262288
  46. Hennersdorf MG, Perings SM, Zühlke C, Heidland UE, Perings C, Heintzen MP, Strauer BE. Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. Intensive Care Med 2002;28:925–9. 10.1007/s00134-002-1317-312122531
  47. Delle Karth G, Schillinger M, Geppert A, Haumer M, Gwechenberger M, Meyer B, et al. Ibutilide for rapid conversion of atrial fibrillation or flutter in a mixed critically ill patient population. Wien Klin Wochenschr 2005;117:92–7. 10.1007/s00508-004-0297-415773423
  48. Kane S, Hanes S. Impact of hydrocortisone on atrial fibrillation in septic shock. Crit Care Med 2014;42:A1588. 10.1097/01.ccm.0000458443.11317.7a
  49. Mayr A, Ritsch N, Knotzer H, Dünser M, Schobersberger W, Ulmer H, et al. Effectiveness of direct-current cardioversion for treatment of supraventricular tachyarrhythmias, in particular atrial fibrillation, in surgical intensive care patients. Crit Care Med 2003;31:401–5. 10.1097/01.CCM.0000048627.39686.7912576943
  50. Kyo M, Hosokawa K, Ohshimo S, Kida Y, Tanabe Y, Ota K, Shime N. High serum potassium level is associated with successful electrical cardioversion for new-onset atrial fibrillation in the intensive care unit: a retrospective observational study. Anaesth Intensive Care 2019;47:52–9. 10.1177/0310057X1881181530864476
  51. Chapman MJ, Moran JL, O’Fathartaigh MS, Peisach AR, Cunningham DN. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. Intensive Care Med 1993;19:48–52. 10.1007/BF017092788440799
  52. Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med 1995;23:1816–24. 10.1097/00003246-199511000-000057587256
  53. Yoshida T, Fujii T, Uchino S, Takinami M. Epidemiology, prevention, and treatment of new-onset atrial fibrillation in critically ill: a systematic review. J Intensive Care 2015;3:19. 10.1186/s40560-015-0085-425914828
  54. Balik M, Matousek V, Maly M, Brozek T. Management of arrhythmia in sepsis and septic shock. Anaesthesiol Intensive Ther 2017;49:419–29. 10.5603/AIT.a2017.006129151002
  55. Bosch NA, Cimini J, Walkey AJ. Atrial fibrillation in the ICU. Chest 2018;154:1424–34. 10.1016/j.chest.2018.03.04029627355
  56. Kanji S, Stewart R, Fergusson DA, McIntyre L, Turgeon AF, Hébert PC. Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials. Crit Care Med 2008;36:1620–4. 10.1097/CCM.0b013e3181709e4318434899
  57. Keller M, Meierhenrich R. [New onset atrial fibrillation in patients with sepsis.] Anaesthesist 2017;66:786–94. 10.1007/s00101-017-0334-028660415
  58. Rehberg S, Joannidis M, Whitehouse T, Morelli A. Landiolol for managing atrial fibrillation in intensive care. Eur Heart J supplements 2018;20:A15–18. 10.1093/eurheartj/sux039
  59. Schwartz A, Brotfain E, Koyfman L, Klein M. Cardiac arrhythmias in a septic ICU population: a review. J Crit Care Med 2015;1:140–6. 10.1515/jccm-2015-0027
  60. Shapiro WA, Schulze K. An algorithm for the practical management of the new onset of atrial fibrillation in patients admitted to the ICU. ICU Director 2012;3:179–84. 10.1177/1944451612449649
  61. Sibley S, Muscedere J. New-onset atrial fibrillation in critically ill patients. Can Respir J 2015;22:179–82. 10.1155/2015/39496126057373
  62. Sleeswijk ME, Van Noord T, Tulleken JE, Ligtenberg JJ, Girbes AR, Zijlstra JG. Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients – a clinical framework. Crit Care 2007;11:233. 10.1186/cc613618036267
  63. Tran B. Atrial Fibrillation in Sepsis: Should We Worry? Relias Media; 2018. URL: www.reliasmedia.com/articles/142049-atrial-fibrillation-in-sepsis-should-we-worry (accessed 1 October 2019).
  64. Labbe V, Ederhy S, Fartoukh M, Cohen A. Should we administrate anticoagulants to critically ill patients with new onset supraventricular arrhythmias? Arch Cardiovasc Dis 2015;108:217–9. 10.1016/j.acvd.2015.01.00125858533
  65. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924. 10.1136/bmj.39489.470347.AD18436948
  66. Meierhenrich R, Steinhilber E, Eggermann C, Weiss M, Voglic S, Bögelein D, et al. Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. Crit Care 2010;14:R108. 10.1186/cc905720537138
  67. Seguin P, Laviolle B, Maurice A, Leclercq C, Mallédant Y. Atrial fibrillation in trauma patients requiring intensive care. Intensive Care Med 2006;32:398–404. 10.1007/s00134-005-0032-216496203
  68. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12. 10.1016/0197-2456(95)00134-48721797
  69. Barranco F, Sanchez M, Rodriguez J, Guerrero M. Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. Intensive Care Med 1994;20:42–4. 10.1007/BF024250548163757
  70. Walkey AJ, Hogarth DK, Lip GYH. Optimizing atrial fibrillation management: from ICU and beyond. Chest 2015;148:859–64. 10.1378/chest.15-035825951122
  71. Vieillard-Baron A, Boyd J. Non-antiarrhythmic interventions in new onset and paroxysmal sepsis-related atrial fibrillation. Intensive Care Med 2018;44:94–7. 10.1007/s00134-017-4986-729116333
  72. Walton J. The need for adequate rate control points to amiodarone as the drug of choice for treating critically ill patients with acute onset atrial fibrillation. Crit Care Med 2008;36:3132–3. 10.1097/CCM.0b013e31818be8ad18941343
  73. Trohman RG. Atrial fibrillation in the critically ill: common sense for a common problem. Crit Care Med 2008;36:1681–2. 10.1097/CCM.0b013e31817014d218448943
  74. Intensive Care National Audit and Research Centre. About the CMP. URL: www.icnarc.org/Our-Audit/Audits/Cmp/About (accessed 1 October 2020).
  75. Harrison DA, Brady AR, Rowan K. Case mix, outcome and length of stay for admissions to adult, general critical care units in England, Wales and Northern Ireland: the Intensive Care National Audit. Research Centre Case Mix Programme Database. Crit Care 2004;8:R99–111. 10.1186/cc283415025784
  76. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J 2004;4:103–12. 10.1177/1536867x0400400201
  77. Marubini E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. Hoboken, NJ: John Wiley & Sons; 2004.
  78. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009;170:244–56. 10.1093/aje/kwp10719494242
  79. Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541–54. 10.2307/2530374373811
  80. Harrell J, Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer; 2001. 10.1007/978-1-4757-3462-1
  81. Bedford JP, Johnson A, Redfern O, Gerry S, Doidge J, Harrison D, et al. Comparative effectiveness of common treatments for new-onset atrial fibrillation within the ICU: accounting for physiological status. J Crit Care 2022;67;14–56. 10.1016/j.jcrc.2021.11.005
  82. Johnson AE, Burgess J, Pimentel MA, Clifton DA, Young JD, Watkinson PJ, Tarassenko L. Physiological trajectory of patients pre and post ICU discharge. Annu Int Conf IEEE Eng Med Biol Soc 2014;2014:3160–3. 10.1109/EMBC.2014.694429325570661
  83. Johnson AE, Pollard TJ, Shen L, Lehman LW, Feng M, Ghassemi M, et al. MIMIC-III, a freely accessible critical care database. Sci Data 2016;3:160035. 10.1038/sdata.2016.3527219127
  84. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–7. 10.1016/S0140-6736(07)61602-X18064739
  85. Palmer E, Post B, Klapaukh R, Marra G, MacCallum NS, Brealey D, et al. The association between supraphysiologic arterial oxygen levels and mortality in critically ill patients. a multicenter observational cohort study. Am J Respir Crit Care Med 2019;200:1373–80. 10.1164/rccm.201904-0849OC31513754
  86. Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 2016;183:758–64. 10.1093/aje/kwv25426994063
  87. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363–73. 10.1056/NEJMoa100133720231232
  88. Johnson AE, Kramer AA, Clifford GD. A new severity of illness scale using a subset of acute physiology and chronic health evaluation data elements shows comparable predictive accuracy. Crit Care Med 2013;41:1711–18. 10.1097/CCM.0b013e31828a24fe23660729
  89. Ho KM, Dobb GJ, Knuiman M, Finn J, Lee KY, Webb SA. A comparison of admission and worst 24-hour Acute Physiology and Chronic Health Evaluation II scores in predicting hospital mortality: a retrospective cohort study. Crit Care 2006;10:R4. 10.1186/cc391316356207
  90. Koponen T, Karttunen J, Musialowicz T, Pietiläinen L, Uusaro A, Lahtinen P. Vasoactive-inotropic score and the prediction of morbidity and mortality after cardiac surgery. Br J Anaesth 2019;122:428–36. 10.1016/j.bja.2018.12.01930857599
  91. Fasiolo M, Wood SN, Zaffran M, Nedellec R, Goude Y. Fast calibrated additive quantile regression. J Am Stat Assoc 2020;116:1402–12. 10.1080/01621459.2020.1725521
  92. Huling JD, Mak S. Energy balancing of covariate distributions. arXiv 2020;2004.13962.
  93. Greifer N. WeightIt: Weighting for Covariate Balance in Observational Studies. 2020. URL: https://ngreifer.github.io/WeightIt/ (accessed 1 October 2010).
  94. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399–424. 10.1080/00273171.2011.56878621818162
  95. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986;1:54–75. 10.1214/ss/1177013815
  96. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: Wiley; 1987. 10.1002/9780470316696
  97. Harris S, Shi S, Brealey D, MacCallum NS, Denaxas S, Perez-Suarez D, et al. Critical Care Health Informatics Collaborative (CCHIC): data, tools and methods for reproducible research: a multi-centre UK intensive care database. Int J Med Inform 2018;112:82–9. 10.1016/j.ijmedinf.2018.01.00629500026
  98. National Institute for Health and Care Excellence (NICE). Research Recommendations Process and Methods Guide. London: NICE; 2015.
  99. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823–33. 10.1056/NEJMoa150103526095867
  100. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263–72. 10.1378/chest.09-158419762550
  101. Champion S, Lefort Y, Gaüzère BA, Drouet D, Bouchet BJ, Bossard G, et al. CHADS2 and CHA2DS2-VASc scores can predict thromboembolic events after supraventricular arrhythmia in the critically ill patients. J Crit Care 2014;29:854–8. 10.1016/j.jcrc.2014.05.01024970692
  102. Yao X, Gersh BJ, Sangaralingham LR, Kent DM, Shah ND, Abraham NS, Noseworthy PA. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin k antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. Am J Cardiol 2017;120:1549–56. 10.1016/j.amjcard.2017.07.05128844514
  103. Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, Romiti GF, Marin F, Lip GYH. Predicting bleeding events in anticoagulated patients with atrial fibrillation: a comparison between the HAS-BLED and GARFIELD-AF bleeding scores. J Am Heart Assoc 2018;7:e009766. 10.1161/JAHA.118.00976630371183
  104. Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open 2017;7:e017157. 10.1136/bmjopen-2017-017157
  105. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012;60:861–7. 10.1016/j.jacc.2012.06.01922858389
  106. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 2011;306:2248–54. 10.1001/jama.2011.161522081378
  107. Russell L, Holst LB, Kjeldsen L, Stensballe J, Perner A. Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies. Ann Intensive Care 2017;7:119. 10.1186/s13613-017-0341-y29230562
  108. Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, et al. Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med 2007;30:E93–102. 10.25011/cim.v30i2.98517716547
  109. Granholm A, Zeng L, Dionne JC, Perner A, Marker S, Krag M, et al. Predictors of gastrointestinal bleeding in adult ICU patients: a systematic review and meta-analysis. Intensive Care Med 2019;45:1347–59. 10.1007/s00134-019-05751-631489445
  110. Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data resource profile: Hospital Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol 2017;46:1093–1093i. 10.1093/ije/dyx01528338941
  111. Landesberg G, Gilon D, Meroz Y, Georgieva M, Levin PD, Goodman S, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J 2012;33:895–903. 10.1093/eurheartj/ehr35121911341
  112. Manning WJ, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994;23:1535–40. 10.1016/0735-1097(94)90652-18195510
  113. Louie EK, Liu D, Reynertson SI, Loeb HS, McKiernan TL, Scanlon PJ, Hariman RJ. ‘Stunning’ of the left atrium after spontaneous conversion of atrial fibrillation to sinus rhythm: demonstration by transesophageal Doppler techniques in a canine model. J Am Coll Cardiol 1998;32:2081–6. 10.1016/S0735-1097(98)00508-79857897
  114. Ang EL, Chan WL, Cleland JG, Moore D, Krikler SJ, Alexander ND, Oakley CM. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J 1990;64:256–60. 10.1136/hrt.64.4.2561977430
  115. Gritsenko D, Paris D, Aitken SL, Lee YI, Altshuler J. Amiodarone versus digoxin for rate control in critically ill patients with rapid atrial fibrillation or flutter. J Emerg Crit Care Med 2018;2. 10.21037/jeccm.2018.06.07
  116. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1990;65:679–80. 10.1016/0002-9149(90)91053-92178386
← ConclusionsAcknowledgements →

Attribution. Jonathan Bedford; Laura Drikite; Mark Corbett; James Doidge; Paloma Ferrando-Vivas; Alistair Johnson et al. (2021). Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses. NIHR Journals Library. Copyright © 2021 Bedford et al. This work was produced by Bedford et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited. Licensed under CC BY 4.0. NCBI Bookshelf NBK575620. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support